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Special Article

The Surviving Sepsis Campaign: Basic/
Translational Science Research Priorities*
Clifford S. Deutschman, MD1,2; Judith Hellman, MD3; Ricard Ferrer Roca, MD4,5; Daniel De Backer, MD6;
Craig M. Coopersmith, MD7; for the Research Committee of the Surviving Sepsis Campaign

Objectives: Expound upon priorities for basic/translational science identified in a recent paper by a group of experts assigned
by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine.
Data Sources: Original paper, search of the literature.
Study Selection: By several members of the original task force
with specific expertise in basic/translational science.
Data Extraction: None.
Data Synthesis: None.
Conclusions: In the first of a series of follow-up reports to the
original paper, several members of the original task force with
specific expertise provided a more in-depth analysis of the five
identified priorities directly related to basic/translational science.
This analysis expounds on what is known about the question and
what was identified as priorities for ongoing research. It is hoped
that this analysis will aid the development of future research initiatives. (Crit Care Med 2020; 48:1217–1232)
*See also p. 1245.
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T

he Sepsis-3 Task Force, jointly sponsored by the Society
of Critical Care Medicine (SCCM) and The European
Society of Intensive Care Medicine (ESICM), recently
redefined sepsis as “life-threatening organ dysfunction caused
by a dysregulated host response to infection” (1). One objective
underlying this new definition was to refocus basic research into
the pathobiology of this deadly syndrome. Specifically, the Task
Force members sought to: 1) emphasize that organ dysfunction
is a key, defining characteristic of sepsis; 2) broaden the scope of
investigation to include aspects of the host response beyond immunologic changes; and 3) direct studies toward identifying the
links between the host response to infection and the development
of organ dysfunction. The papers that resulted from the work of
the Task Force have generated both enthusiasm and controversy.
Most of the response, however, has focused not on the redefinition but rather on the evidence-based clinical criteria used by
the Task Force to identify patients with sepsis from patients with
uncomplicated infection. The definition is inherently difficult to
examine in the clinical arena because clinical identifiers of “organ
dysfunction” and “dysregulated host response” are limited. Therefore, the Task Force explicitly stressed that future research into the
basic science of sepsis focus on clinically applicable identifiers of
“organ dysfunction” and “dysregulated host response.”
A second major collaboration between the SCCM and the
ESICM is the Surviving Sepsis Campaign (SSC). In formalizing their joint responsibilities for the SSC, the leaders of both
societies established a Research Committee. The first task of
the committee was to identify future research priorities. The
deliberations of the committee led to the joint publication
of “Surviving Sepsis Campaign Research Priorities for Sepsis
and Septic Shock” in the journals Critical Care Medicine and
Intensive Care Medicine in August 2018 (2, 3). The initial document presented a broad overview of research priorities in
several critical care domains with an expressed intention to, in
the future, publish separate papers with more detailed descriptions for each domain. This paper, focusing on basic/translational science, contains the effort to fulfill that promise.
www.ccmjournal.org
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METHODS
The content of the initial paper published by the SSC Research
Committee (2, 3) was developed by asking each committee
member to identify the research questions that most urgently
required answers. Using a modified Delphi approach, the Task
Force members reduced the original 88 suggestions to a series
of questions focused on clinical care and four directed toward
“basic science.” The final queries were presented in the original
publication. Three Task Force members with specific expertise
were tasked with generating expanded reviews of the four basic
science questions as well one additional query focusing on epigenetics. Each question was addressed by one of the three task
force members. These in-depth reviews were then edited by the
group as a whole, with added input from the committee cochairs. The final result is presented here.

OVERVIEW OF THE PRESENTATION
The five basic science questions identified by the Task Force as
a whole as follows:
1) What mechanisms underlie sepsis-induced cellular and
subcellular dysfunction?
2) How does sepsis alter bioenergetics and/or metabolism
(both enhancement and failure)?
3) How does sepsis (and/or approaches used to manage
sepsis) alter phenotypes and interactions in the host
microbiome and do alterations in the microbiome affect
outcomes?
4) How do epigenetics influence the pathobiology of sepsis?
5) What mechanisms initiate, sustain, and terminate recovery after sepsis?
The format for each of the five questions directly mirrors
that used in the previously published overview, which contains
a more extensive description of the methods (2, 3).
Question 1: What Mechanisms Underlie SepsisInduced Cellular and Subcellular Dysfunction?
What Is Known.
The redefinition of sepsis by the Sepsis-3 Task Force focuses
on the importance of organ dysfunction as the sine qua non
of the disorder (1). As a result, there is a compelling need to
develop new clinical constructs for dysfunction in individual
organ systems, as well as to continue to advance animal models to more accurately reflect human sepsis (4). The process is
hampered by 1) lack of a true gold standard to identify sepsis
and 2) a need to develop indices of organ dysfunction that can
be measured in patients, where access to cells is limited. There
is little to be done about the first point. To address the second,
it will first be necessary to identify the cellular abnormalities
that underlie dysfunction in specific organ systems. These
abnormalities can then be related to updated proxy measures
that correlate, as closely and specifically as possible, with the
actual cellular changes that lead to sepsis-induced organ dysfunction. However, access to clinical samples is limited, most
often to what can be obtained from sampling blood, urine, or
1218
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less frequently with biopsy or lavage specimens. Thus, WBCs
are likely to be all that is routinely available. As a result, there
is an imperative to use either models or in silico constructs to
identify cellular abnormalities consistent with sepsis-induced
dysfunction in different organs. Correlation of these abnormalities with measurements that can be made using blood or
urine, or with noninvasive functional testing (e.g., echocardiography) will provide a clinically useful approach to organ
dysfunction.
A) Pathobiological changes that constitute “dysfunction” have
been identified in several organ systems. These abnormalities
reflect a small number of identifiable patterns.
1) Some pathobiological abnormalities are consistent with
changes in clinical variables that are commonly measured. These changes can therefore be used to indicate
the presence of organ dysfunction and to follow its clinical course. For example, pathologic abnormalities in
the lung (edema in intra-alveolar septa and air spaces,
debris—the “hyaline membrane”—lining alveoli, loss
of type 1 pulmonary epithelial cells via necrosis and apoptosis, loss of synthetic capacity by type-2 cells) (5–7)
are consistent with the clinical presentation of lung injury (development of hypoxemia, reduced compliance,
atelectasis, and multifocal lung consolidation) that are
often used to assess respiratory function in patients.
2) In other cases, changes consistent with organ dysfunction have been identified under experimental conditions and in animal models. However, these variables are
not routinely measured clinically, nor have surrogates
that correlate with these abnormalities been clinically
validated. For example, sepsis-induced abnormalities in
hepatic detoxification (e.g., transcellular bile acid transport) and biosynthesis (e.g., hepatocellular gene expression) have been described at the basic level (8–10).
However, these variables are not currently measured in
the clinical realm, where hepatic dysfunction from any
cause is assessed using serum levels of transaminases and
elevations of bilirubin that are relatively nonspecific and
not diagnostic of sepsis-induced hepatocellular dysfunction. Thus, a better understanding of pathobiology is required to identify measurements with clinical utility.
3) Although some aspects of sepsis pathobiology have been
well-described, their significance can be interpreted in
two completely contradictory ways. As an example, consider sepsis-induced abnormalities in WBCs, which include elevated cytokine elaboration, reduced bacterial
killing/clearance, and depressed responses to stimulation
with inflammatory agonists (11). However, elevated cytokine expression can reflect the response to two different, diametrically opposite stimuli. High levels of tumor
necrosis factor (TNF)-α or interleukin (IL)-6 can induce
inflammation and may directly damage cells. Thus, the
increased elaboration might in itself be pathologic; appropriate therapy would therefore be blockade of their
August 2020 • Volume 48 • Number 8
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activity. However, in animal models of sepsis, there is impairment of intracellular pathways that are activated by
these cytokines—that is, cells do not have the expected
response to cytokines. The adaptive response to this situation would be to overcome the defect with increased cytokine elaboration and release, much as primary adrenal
insufficiency results in enhanced release of thyroid-stimulating hormone from the pituitary (12). If elevated
levels of TNF-α and IL-6 represent a compensatory
mechanism to counteract these defects, therapy would
involve increasing TNF/IL-6 abundance or activity even
further. It is conceivable that both possibilities can occur
concurrently. That is, the response of some cells to cytokines may be inadequate (e.g., hepatocytes, as identified
in animal models), which drives up levels of IL-6 and
TNF-α. These high levels, however, may be toxic to other
cells (e.g., pulmonary or gastrointestinal tract [GI] epithelial cells). In effect, the elaboration and secretion of
cytokines may be driver of pathology, a beneficial response to pathology, both, or an incidental change. Thus,
while it is clear that sepsis elevates TNF-α/IL-6 levels, a
better understanding of the impetus underlying these
changes is required to intervene effectively.
4) In some cases, it may be impossible to separate sepsis
pathobiology from the effects of treatment. The best example lies in attempts to differentiate acute respiratory
distress syndrome (ARDS) from ventilator- or fluidinduced lung injury. A better understanding of differences in the cellular pathobiology of these disorders is
therefore required.
5) Certain aspects of sepsis pathobiology have proven remarkably difficult to understand. Evidence may suggest the presence of global organ dysfunction and of
abnormalities in processes specific to certain cell types,
but it is difficult to sort out the complex combination
of dysfunction in individual types of cells and the interaction between these cells. Consider sepsis-induced
acute kidney injury. Identified specific abnormalities
include 1) reduced glomerular filtration rate (GFR) despite, 2) adequate or high renal blood flow (RBF) (13), 3)
poorly understood defects in tubular function (14), and
4) aberrant or attenuated responses to exogenous modulation, for example, by hormones. Although a comprehensive explanation that encompasses all of these
defects has been proposed (14) and appears to be present in a rodent model (15), it has not been validated
in large animals or in clinical sepsis. Decreased GFR
despite adequate or supra-normal RBF can reflect dilation of the efferent (postglomerular) arteriole, but how
this change might relate to altered resorption and transport in the tubules is unknown. Correlations between
changes in biomarkers for GFR (serum levels of creatinine, neutrophil gelatinase-associated lipocalin [NGAL],
or cystatin-C) and those reflecting tubular dysfunction
(kidney injury marker [KIM]-1, insulin-like growth factor binding protein [IGFBP]-7) are lacking. How KIM-1
Critical Care Medicine

and NGAL IGFBP-7 are related to actual defects in tubular function is unclear. Further, it is difficult to differentiate the risk of renal compromise (often termed
“stress”) from actual dysfunction or injury. That is, an
early period of inflammatory activation and perhaps
proximal tubular dysfunction/injury precedes abnormalities (uremia, acidosis, abnormal electrolyte levels
such as hyperkalemia) that have historically been used to
indicate a need for renal replacement therapy. As is the
case with other organs (e.g., heart, liver), the correlation
between dysfunction and histologic evidence of damage
is obscure. Thus, a far more complete understanding of
the pathobiologic changes that cause dysfunction in different types of cells and/or processes in individual organ
systems and of how sepsis disrupts interactions between
different types of cells is of key importance.
B) Sepsis pathobiology may reflect dysfunction is closely related cell types that are present in a number of distinct organ
systems. For example, experimental and clinical evidence indicates the presence of sepsis-induced defects in protein synthesis in hepatocytes, type 2 pulmonary epithelial cells, and
“central,” that is, pituitary, endocrine cells (5–10, 16–20). Conversely, each cell or type of cell may develop a specific defect or
manifest dysfunction in a unique manner. For example, sepsis
upregulates production and release of cytokines by monocytes
and lymphocytes (11) but decreases production and release of
surfactant or surfactant proteins by type II pulmonary epithelial cells (5–7) or of hormones by endocrine or pituitary cells
(18–20).
C) As mentioned above, sepsis is associated with defects in
cytokine signal transduction pathways. Data suggest that this
type of abnormality may alter the response to other mediators. Impairment of endocrine signal transduction in sepsis
has been well-described (19). Sepsis also downregulates
β-adrenergic and other G-protein receptor-mediated pathways
(21, 22), which contributes to sepsis-induced cardiac dysfunction (23). More recent data indicate defective signal transduction in pathways responding to steroid hormones, for example,
glucocorticoids (24).
D) There is an important extension of the described defects
in cytokine- and hormone-mediated cellular responses. Cytokines, which are primarily produced by immune and endothelial cells, and hormones, which circulate, represent pathways by
which cells in one tissue or organ system can be “informed” of
changes that occur elsewhere. For example, a decrease in blood
pressure or oxygen content in the blood supplying the brain is
sensed by specialized cells of the carotid artery and trigger the
release of epinephrine, vasopressin, and angiotensin, which in
turn increase cardiovascular function, thereby restoring substrate delivery to the brain. Similarly, immune and endothelial cells respond to the presence of either damage-associated
molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) by elaborating and releasing cytokines,
which can then alter activity in adjacent cells. Activation of circulating immune cells makes it possible for the transmission
of DAMP/PAMP—induced responses to remote cells, tissues,
www.ccmjournal.org

1219

Deutschman et al

and organ systems. In effect, endocrine and immune changes
function, in part, as part of an organism-wide communications system. Sepsis impairs these forms of communication by
attenuating the ability of cells to respond to cytokine and endocrine mediators.
A third major long-range communication system within
organisms is the nervous system. Multiple lines of evidence indicate that sepsis induces impairment in both the peripheral
nervous system and CNS (25–28). The peripheral neuropathy
of sepsis/critical illness has been well-described. Several more
recent findings have demonstrated that sepsis impairs signaling originating in the brain that limits responses in other organ
systems. The orexinergic system of the hypothalamus was recently reported to modulate, at least in part, depressed activity/
arousal, bradycardia, hypothermia, and hypopnea in experimental sepsis (analogous to the tachycardia, hyperthermia, and
tachypnea that initially characterize the human response). This
defect in orexinergic signaling also alters pituitary hormone release. All these changes were reversed when orexin was administered into the cerebrospinal fluid (27). Finally, sepsis interferes
with the “inflammatory reflex,” a negative feedback loop in the
vagus nerve where ascending signals “inform” the brain of inflammatory events in the periphery while descending signals
limit the cytokine response to those same responses (28–31).
A number of studies have demonstrated brain inflammation in
experimental sepsis, most often implicating microglia (29, 30).
E) A substantial body of evidence suggests that sepsis causes
a global defect in a basic cellular or subcellular function in
many cell types. The ubiquitous presence of such an abnormality would produce dysfunction in many different cell types,
irrespective of their specific function or location. For example,
there are numerous reports of sepsis-induced mitochondrial
dysfunction in multiple cell types (19, 20, 27). Abnormalities
have been reported in mitochondrial oxidative phosphorylation, with impairment described in all four complexes of the
electron transport chain (ETC) (32–36). The resulting energy
deficit could disable cell-specific functions in any cell that is
mitochondria-dependent.
F) Finally, dysfunction in a single type of cell that is present in
virtually all organs could underlie cell- and organ-specific dysfunction. For example, endothelial cells, which are present in
all tissues, actively produce inflammatory mediators and coagulation intermediaries during sepsis and contribute to sepsisinduced vascular dysfunction and leak (18, 37). Thus, differential
or sequential development of endothelial dysfunction in different vascular beds might mediate aspects of sepsis-induced organ
dysfunction.
What Is Not Known—Gaps in Our Understanding—Directions
for Future Research.
1) Does a global defect that is shared by multiple cell types
underlie all forms of sepsis-induced cellular dysfunction?
2) Are there unique mechanisms of dysfunction that are
specific to different types of cells, including different
types of cells within a single organ?
1220
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3) Do cells of similar embryologic origin (e.g., epithelium)
become dysfunctional in ways that differ from other
types of cells?
4) Do cells with similar functions (e.g., elaboration/release
of proteins, lipids) develop unique forms of dysfunction
that differ from that of cells with different basic functions (e.g., all cells that contract)?
5) Endothelial cells are present in virtually all organ systems and may directly modulate organ function. Does
endothelial cell dysfunction underlie dysfunction in
other organ systems?
Question 2: How Does Sepsis Alter Bioenergetics
and/or Metabolism (Both Enhancement and Failure)?
What Is Known.
Many of the effects of sepsis on bioenergetics and/or metabolism have been well-described (38, 39). In general, sepsis is
associated with an increase in metabolic rate, as reflected in oxygen consumption and overall substrate utilization (40). There
is, however, a reduction in adenosine triphosphate (ATP) utilization in many tissues (41–44). This limitation occurs in concert with maintenance of ATP abundance, suggesting that the
decreased use reflects an attempt to conserve ATP availability
to avoid cell death (45). In this setting, “aerobic glycolysis” is
stimulated and assumes a greater role in ATP production. That
is, despite what would appear to be more than adequate oxygen
availability, substrate is shunted into the glycolytic pathway,
resulting in the generation of lactate. Sepsis differs from other
states where aerobic glycolysis is present (e.g., aerobic exercise)
because of the ability of the liver to use lactate for gluconeogenesis (the Cori cycle) or bicarbonate is impaired (46). This
limitation contributes to hyperlactatemia and a metabolic acidosis. Thus, the aerobic glycolysis of sepsis constitutes a clinical
example of the Warburg effect (47–49).
Two explanations for the sepsis-induced changes in glycolysis have been advanced. The first posits that increased glycolysis in sepsis reflects a defect in the microvasculature that
impairs the delivery of oxygen to metabolically active tissues.
Interestingly, the changes may be attenuated by hemodynamic
targeted interventions (50). The alternative implicates a defect
in mitochondrial function that leads to a decrease in oxygen
utilization. The latter is supported by abundant evidence of defective oxidative phosphorylation in sepsis. Importantly, these
two putative mechanisms are not mutually exclusive; indeed,
evidence suggests that both are operative in sepsis. Which specific complexes in the ETC are impaired is incompletely understood, and appears to depend on the tissue, or, in animals, the
model. Decreased activity has been identified in each of the five
complexes in ETC (33, 34). Importantly, complex II serves as
an enzyme in both oxidative phosphorylation and in the Krebs
cycle. Therefore, impairment would enhance the diversion of
substrate into glycolysis, a change that has been hypothesized
to underlie the Warburg effect (51). One of the consequences
of impaired mitochondrial function, whether as a result of
a defect in either the microcirculation or the mitochondria
August 2020 • Volume 48 • Number 8
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themselves, has been termed “hibernation” or “oxygen conformance” (52–54). In this state, nonvital functions are shut
down in order to maintain cell viability despite inadequate oxygen delivery or utilization.
Sepsis is also known to alter substrate preference, with a
relative decrease in the utilization of glucose (glucose intolerance) relative to fat and protein (55–57). As a result, septic
patients tend to be hyperglycemic. In later stages, oxidation of
fatty acids may also be impaired, as reflected in elevated serum
levels of lipoproteins, free fatty acids, and triglycerides (47–49).
There is accelerated catabolism of skeletal muscle and possibly
smooth muscle as well (58). In addition, the effects of micronutrient (e.g., vitamins, trace metals) are also impaired, reflecting either deficiency or altered activity (59).
Changes in metabolism may also reflect the influence
of “communications” pathways (described under question
1)—humoral (i.e., cytokine/white cell-mediated), endocrine,
neuronal—on cellular function. Cytokine-mediated changes are
well-described; the initial description of the metabolic effects of
TNF was based on observations in diseased cattle—cachexia despite grossly lipemic serum. Studies in clinical sepsis and/or animal models have identified impaired activity of hormones that
are known to affect metabolism (e.g., insulin, glucagon, T3/4,
growth hormone, epinephrine/norepinephrine cortisol) and of
less well-studied endocrine agents (adiponectin, leptin, ghrelin).
Indeed, relative endocrine resistance is a characteristic finding
(60). Some studies suggest that sepsis alters the CNS effects of
leptin and ghrelin, which are integral in central modulation of
metabolism (61, 62). Recent studies implicate alterations in the
activity of the orexinergic and basal forebrain muscarinic systems in the brain in sepsis-induced metabolic changes (27, 28).
Several recent cohort studies and meta-analyses have suggested a protective role for obesity in critically ill patients (63–
65). However, the data are far from conclusive and mechanistic
explanations are lacking. Indeed, basic studies in mice suggest
that diet-induced obesity increases sepsis-induced inflammation as well as injury to the heart and liver (66–69).
What Is Not Known—Gaps in Our Understanding—Directions
for Future Research.
1) What causes the increased metabolic rate noted in sepsis?
2) What mechanisms mediate alterations in oxidative phosphorylation? In particular, what underlies the altered activity in specific ETC complexes?
3) What mechanisms alter sepsis-induced changes in
pathway (e.g., glycolysis, beta-oxidation, nitrogen cycle),
substrate (e.g., carbohydrate, fat, protein, micronutrient), and/or cell (e.g., cardiomyocyte, hepatocyte) specific metabolism?
4) What mechanisms underlie sepsis-induced defects in endocrine activity?
5) How does sepsis affect brain circuits that control
metabolism?
6) How do cytokines alter metabolic pathways?
7) Do metabolic pathways influence inflammation, and if
so, how?
Critical Care Medicine

8) Are changes in energetics observed in all cells or are they
cell-type-specific?
9) Are defects affecting energetics present only in mitochondria or are there also changes in other subcellular
structures?
10) Is obesity protective against sepsis? Why are results in
human sepsis and animal models discrepant?
Question 3: How Do the Microbiota and the
Microbiome Contribute to the Pathobiology of Sepsis?
What Is Known.
In a number of disease states, pathology is determined by an
alteration in the interactions between the host and its complex microbial ecosystem. These changes, which likely affect
outcomes of critically ill and septic patients, are the subjects
of intense clinical and basic science investigations. The development of culture-independent methods to detect microbial
genes has revolutionized this research and greatly enhanced
microbe identification (70–72). We now appreciate the enormous diversity of microbial species (microbiota) and microbial
genomes (microbiome) that exist within human ecosystems
(e.g., GI tract [gut], lungs, skin, etc.), as well as the importance
of the microbiome to human health and disease (70). It has become clear that the gut microbiome plays an important role in
patients with sepsis, suggesting that the microbiome and hostmicrobiome interactions may be therapeutic targets (73).
The average healthy 70 kg adult human male is estimated to
contain approximately 30 trillion host cells and to be colonized
by nearly 40 trillion microbes (72, 74). The gut microbiome
is the largest in the human body and, perhaps because it can
be assessed using fecal samples, has been the most extensively
studied microbiome. The gut contains over 1,000 species of
bacteria, fungi, protozoa, and viruses containing nearly 9.9
million microbial genes (75). These microbes live in complex
and interactive communities and exhibit extensive geographic
heterogeneity (75).
Recent studies indicate that the gut microbiome contributes
to the regulation and maturation of biological function both
within and outside of the GI tract (76). The gut microbiome
contributes to 1) pathogen containment, 2) immune maturation and functionality within and outside of the GI tract, 3)
neurologic signaling, 4) host cell proliferation, 5) toxin elimination and drug modification, and 6) biosynthesis of compounds, including vitamins and neurotransmitters (77–84).
Dysbiosis, the development of imbalances in the composition
and/or function of the host microbiome, has been implicated
in a wide variety of human and animal disorders, including
cardiovascular disease, autism spectrum disorders, metabolic
disorders, and asthma (85–91). Importantly, host-microbiota
interactions are bi-directional; the two impact each other
enormously.
A number of studies have suggested that the host microbiome is altered both by sepsis itself and by management
approaches used to treat septic patients. Some have gone so far
as to postulate that these changes contribute to the multiple
www.ccmjournal.org
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organ dysfunction syndrome (MODS) (76, 92–94). Alverdy
and Krezalek (95) defined mechanisms by which they believe
the microbiome becomes a “pathobiome” (95–99) that leads to
“nonresolving MODS)” (95, 96, 100).
A) Multiple endogenous host and external factors contribute
to the conversion of a healthy microbiome into a pathobiome
in patients with sepsis.
Clinical studies have documented changes in the number
of microbial species and genes, pathogenicity of different
microbes, and microbial production of metabolites in the gut
microbiome of adult patients following hepatectomy, trauma,
cardiac arrest, and cerebrovascular events (101–104). Clinical
studies in the ICU arena have primarily focused on the microbiome of the general ICU population and not specifically on
the subset of patients with sepsis. Sepsis-induced changes
were suggested by a small clinical study of patients with severe
systemic inflammatory response syndrome caused by sepsis
(n = 18), trauma (n = 6), and burns (n = 1) (102) and likely
contribute to findings in critically ill adults (100) and children
(104). Enrichment of the lung microbiome with gut bacteria
has been reported in mice that have undergone cecal ligation
and puncture (CLP) (105), a widely used model of abdominal
sepsis that was first described in 1980 (106), and in critically ill
patients with ARDS (105). Finally, alterations in the gut microbiome have been reported in mice following experimental
brain injury (107).
A number of factors alter the composition and pathogenicity of the human microbiome (Table 1) (73, 75, 78,
108–114). Although the relative contribution of each of these
factors to clinical changes in the microbiome during critical
illness is difficult to discern, antibiotics, and severity of illness
seem to be major determinants (73).
Basic research directed at identifying the mechanisms underlying both gut dysbiosis and changes in the microbial virulence
in species such as Candida, Staphylococcus, and Pseudomonas
(79, 97, 99) has identified a number of contributors. Factors involved in the latter are both intrinsic (hormones, endorphins)

Factors Contributing to the
Development of Gut Dysbiosis
TABLE 1.
Factors

Host factors

Geographic location

(75)

Exposures to microbes in the
environment

(110)

Diet

(112)

Drugs: antimicrobial agents,
immunosuppressive agents, etc.

(78, 108)

Genetic factors

(109, 111)

Immune health/responses
Diseases/disorders/infections
Severity of critical illness
1222
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B) Gut dysbiosis and the development of a pathobiome is associated with worse outcomes in septic patients.
Clinical studies suggest that sepsis is associated with the
replacement of a diverse, health-promoting microbiome by
a pathobiome that is harmful to the host (92, 94, 118, 119).
Animal studies support the contribution of this dysbiosis to
septic pathobiology and MODS (120–122). Dysbiosis is characterized by an altered microbiome that eliminates microbes such
as Lactobacillus and Bifidobacterium that protect against overgrowth and limit epithelial adherence of pathogenic bacteria
(123, 124). The protective effects of the healthy microbiome
may lie in the ability of Lactobacillus and obligate anaerobes to
ferment nondigestible dietary fibers to short-chain fatty acids
(SCFAs), including propionate, acetate, butyrate, that can be
used by the gut epithelium to promote barrier integrity and
enhance immune function (124–126). This loss can promote
systemic infection and dysregulated inflammation.
C) Manipulation of the gut microbiome affects outcomes from
infection and alters immune responses in some conditions.
Therapeutic manipulation of the gut microbiome via selective decontamination, fecal transplantation, or use of probiotics has been attempted in several conditions attributed to
gut dysbiosis. This approach is supported by studies in animals (127–133). A number of studies have documented that
selective gut decontamination in both humans and animals
reduced organ inflammation and dysfunction (134, 135). Fecal
transplantation has shown efficacy for severe recurrent diarrhea caused by antibiotic-resistant Clostridium difficile and has
mixed results in inflammatory bowel disease, but its utility in
critically ill patients has yet to be defined (136–139).
D) What environmental factors could be manipulated to promote a healthy microbiome?

References

Exogenous

and extrinsic factors (opiates, antibiotics, immunosuppressive
agents). Recent studies have invoked quorum sensing, a complicated system that allows microbes to collectively respond to
the environment (97, 116, 117). Pseudomonas aeruginosa has
been reported to adopt a more virulent phenotype in response
to exogenous and endogenous opioids via quorum sensing
mechanisms (97).

(115)
(76, 109)
(73)

Although it may be difficult to forgo treatment with essential therapies such as antibiotics, other factors, such as diet,
stress ulcer prophylaxis, and the use of immunosuppressive
agents, are potentially amenable to interventions. Although
some cannot be changed (e.g., host genome), understanding
their impact on the host’s microbiome may eventually lead to
personalized approaches to manipulating the host’s environment to promote a healthy microbiome.
E) How do the microbiomes from different parts of the body
determine outcomes?
Thus far, studies on how the changes in the microbiome affect
critically ill patients have focused on the gut. However, critical
illness and sepsis also cause changes in other microbiomes, such
August 2020 • Volume 48 • Number 8
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as the lung (105). The importance of non-GI microbiomes in
determining outcomes of sepsis has yet to be defined.
What Is Not Known—Gaps in Our Understanding—Directions
for Future Research.
1) How do specific approaches to the management of sepsis
affect the host microbiome?
2) Which of the factors noted in Table 1 promote gut dysbiosis? What are their specific effects? Are other factors
are involved?
3) Do changes in the microbiome directly lead to the development or exacerbation of sepsis/MODS? What specific components of the pathobiome are of particular
interest?
4) Does the conversion from a normal microbiome to a
pathobiome cause/exacerbate sepsis MODS or is the
change merely associated with sepsis/MODS?
5) Does manipulation of the microbiome alter the incidence, severity, or outcomes of sepsis?
6) Can the pathobiome be stably converted back to a
normal microbiome? Is such a conversion beneficial?
7) Does the presence/absence of SCFA affect the pathogenesis of sepsis? Does it affect organ dysfunction or sepsis
outcomes? Does administration of SCFAs or the introduction of SCFA-producing bacteria alter sepsis pathogenesis and/or improve organ dysfunction and outcomes?
8) What environmental factors could be manipulated to
promote a healthy microbiome? Does manipulating diet,
exercise, or immunosuppressive agents affect the development of sepsis/MODS? Does it alter outcomes?
9) Can a better understanding of how host genomics interact with specific elements in the microbiome/pathobiome provide insight that can alter outcomes? Can this
understanding be leveraged to provide personalized
approaches to the promotion of a healthy microbiome?
10) Are prebiotics or probiotics therapeutically beneficial? Is
fecal transplantation beneficial?
Question 4: How Do Epigenetics Influence the
Pathobiology of Sepsis?
What Is Known.
“Epigenetics” is a catch-all phrase used to describe alterations
in gene expression that occur independent of changes in DNA
sequence. It is increasingly evident that these alterations are essential determinants of human health and diseases (140). Epigenetic alterations are dynamic, and under optimal conditions,
serve beneficial functions. However, these changes can also
contribute to the development of major diseases and disorders,
as well as affecting outcomes in more subtle ways. Importantly,
epigenetic changes can be heritable. Epigenetic changes may
alter the host response to infection and injury, and therefore
the ability to prevent or clear infection.
Epigenetic mechanisms include DNA methylation, histone
modifications (methylation, acetylation, phosphorylation,
ubiquitination, and glycation), and elaboration of microRNAs
Critical Care Medicine

(miRNAs). All can lead to rapid, transient, and reversible modification of gene expression by inducing gene activation or
silencing. Studies in humans and animals suggest that epigenetic modifications impact sepsis (140, 141).
A) Sepsis and endotoxemia are associated with epigenetic alterations in myeloid cells and in modulation of inflammation.
DNA methylation, histone modifications, and altered levels of
miRNAs have been observed in cells in endotoxemia and sepsis.
The changes in gene expression associated with these modifications modulate responses that may lead to endotoxin tolerance,
immunosuppression, and immunoparalysis and susceptibility
to infections (142–152). DNA and histone methylation can silence genes encoding inflammatory mediators, anti-oxidants,
and other factors that contribute to systemic inflammation
(146, 152, 153). In contrast, DNA methylation at certain genes
has been linked to excessive systemic inflammation (147, 149).
B) Lung injury induces epigenetic modifications that promote
vascular permeability.
Experimental lung injury induced modification of histone H3 and thus downregulation of angiopoietin 1, Tie2, and
Vegfr2. These changes, in turn, have been implicated in the expression of genes encoding inflammatory mediators and in the
development of excessive microvascular permeability (154).
C) Histones and miRNAs circulate in sepsis and may contribute to organ dysfunction.
Animal and human studies have shown that histones circulate in sepsis and are associated with increased mortality
rates (155, 156). miRNAs have also been found to circulate in
human sepsis (157–160). In CLP mice, miRNAs that circulate
in extracellular vesicles have been implicated in the development of inflammation (161).
D) Epigenetic alterations are being explored as potential sepsis
biomarkers and therapeutic targets.
Epigenetic alterations, including DNA methylation, histone
modifications, and miRNAs, have been touted as diagnostic
biomarkers, markers of disease severity, and therapeutic targets
(155, 162–164). Studies on utility, which has been demonstrated
in cancers (165), are being explored in sepsis (163, 166–172).
What Is Not Known—Gaps in Our Understanding—Directions
for Future Research.
1) Are epigenetic changes such as DNA methylation, histone modifications, and miRNA expression important
contributors to the development of sepsis?
2) Do epigenetic changes contribute to sepsis-induced
MODS or changes in immune function? Or are they
merely epiphenomena?
3) Can epigenetic changes be used as diagnostic and/or
prognostic biomarkers?
4) Are epigenetic alterations potential therapeutic targets in
sepsis?
5) Might existing drugs (e.g., HDAC modulators) be used
www.ccmjournal.org
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or new drugs be designed to target epigenetic alterations
in sepsis?
6) How do epigenetic factors influence the microbiome,
and vice versa, and what are the implications for sepsis?
Question 5: What Mechanisms Initiate, Sustain, and
Terminate Recovery After Sepsis?
The phrase “recovery from sepsis” can have a broad meaning. On
an organism, wide level recovery can mean survival, reversal of
organ dysfunction, or resumption of premorbid activities. Control/elimination of the focus of infection is required but it is by
no means sufficient. Indeed, organ dysfunction can persist for a
prolonged period afterward; some sepsis-induced abnormalities
may never fully resolve. Overall, recovery likely reflects reversal
of a vast array of maladaptive cellular, subcellular, and biochemical changes that develop during sepsis. These alterations involve
metabolism, dysfunction in organelles, in particular mitochondria, attenuation of intracellular signal transduction pathways
and decrement in the activity of WBCs, neuronal pathways and
endocrine responses that are responsible for the transfer information from one part of the organism to another.
Despite reports that describe the events occurring during
recovery or lack of recovery, the specific mechanisms that initiate recovery are unknown. It is possible that recovery represents an extension of Darwinian theory: sepsis resolves and the
fittest cells/patients survive by implementing general mechanisms of protection. Alternatively, it may be that specific molecules/processes/ events directly promote recovery from sepsis.
Or perhaps recovery represents a combination of both.
A) What immunological processes contribute to recovery from
sepsis?
In contrast to a substantial body of work describing the resolution of “normal” or “balanced” inflammation, much about
the reversal of the unique inflammatory state present in sepsis
is poorly understood. Perhaps the greatest hindrance lies in a
limited ability to characterize that state. To some extent, sepsis
resembles an exaggeration of normal inflammation, with expression of high levels of pro-inflammatory cytokines. Other
aspects, such as white cell bacterial engulfment and bacterial
killing, are impaired. However, the combination of immune
excess and immure incompetence characteristic of sepsis is
strikingly unusual. It is logical to assume that the resolution of
sepsis will be similarly difficult to understand. Thus, the complexity of the issue is apparent and requires attention.
1) Do anti-inflammatory cytokines contribute to recovery
after sepsis? If so, how?
What Is Known.
Resolution of sepsis-induced inflammation is an active process
that likely involves the production of endogenous anti-inflammatory molecules. A number of anti-inflammatory cytokines are
upregulated during the course of sepsis (e.g., IL-1RA, IL-4, IL-10,
and TGF-β) (173–175). Importantly, IL-4 alters the balance between pro-inflammatory and anti-inflammatory T lymphocyte
phenotypes and participates in the regulation of proliferation,
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differentiation, and apoptosis in multiple cell types. These IL4-mediated changes are important for resolution of nonseptic
inflammation but may actually contribute to the pathobiology
of sepsis (176). IL-10, in turn, blocks synthesis of interferon-γ,
IL-1, TNF-α, IL-12, and GM-CSF and enhances the endocytosismediated elimination of human leukocyte antigen (HLA)-DR
for the surface of white cells (177). Again, these activities contribute to the resolution of inflammation under normal circumstances but how they influence sepsis is unclear. Indeed, clinical
trials of a number of “anti-inflammatory” mediators have not
demonstrated benefit in patients with sepsis (178).
What Is Not Known—Gaps in Knowledge.
• How do cytokines (IL-1RA, IL-4, IL-10, and TGF-β)
with known anti-inflammatory effects contribute to the
resolution of sepsis? What other white cell mediators
contribute?
• Does the activity of IL-1RA, IL-4, IL-10, and/or TGF-β
contribute to sepsis-associated immunosuppression?
What other mediators are involved?
• Is the balance between pro- and anti-inflammatory activities that mediate recovery from “normal” inflammation lost in the resolution of sepsis?
2) What processes in immune cells other than cytokine elaboration and release contribute to the resolution of sepsis?
What Is Known.
As mentioned, sepsis is associated with a poorly understood defect in bacterial engulfment and killing by leukocytes (27). In
normal inflammation, the endocytosis-mediated elimination of
HLA-DR for the surface of white cells by IL-10 plays an important role (177). Changes in lymphocyte expression of the inhibitory receptor programmed death 1 (PD-1) and changes of T cell
receptor diversity occur during healthy recovery from nonseptic
conditions. However, it is unclear whether a similar process in
sepsis leads to a healthy resolution of inflammation or if it represents an additional manifestation of sepsis pathobiology. PD-1
has been implicated in sepsis-associated immune suppression in
both animals and humans (179, 180). PD-1 overexpression by
circulating T cells has been detected in septic patients and correlates with worse outcomes (179); further, normalization of PD-1
expression at day 7 was noted in septic shock survivors (180).
A number of processes are known to contribute to limitations in normal/balanced inflammation. For example, lipoxin
A4 regulates MCP-1 and nonphlogistic monocyte recruitment and stops LTB4-stimulated PMN influx (181). Similarly,
maresins, protectins, and resolvins limit further PMN influx to
the site and stimulate efferocytosis and the clearance of cellular
debris by resolving macrophages (181). Autophagy-related
proteins that act as critical regulators of caspase-1 activation
(e.g., beclin-1 and LC3B) in vitro and in vivo, contribute to
normal/balanced inflammation by preventing accumulation
of physiologically abnormal mitochondria (182). miRNAs,
such as programmed miR-466l expression, are temporally
and differentially expressed during the resolution of balanced
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inflammation (183). Impairment of any of these processes
might contribute to failed resolution of sepsis.
What Is Not Known—Gaps in Our Understanding—Directions
for Future Research.
• Sepsis is associated with impairment in a number of
processes that contribute to resolution of normal/
balanced inflammation. Does resolution of this defect contribute to recovery from sepsis? Or, conversely,
does recovery from sepsis lead to resolution of these
abnormalities?
• Does the PD-1 pathway exacerbate sepsis pathobiology
or does it enhance recovery?
• Do lipid mediators, autophagy, or miRNA, which contribute to resolution of balanced inflammation, also
contribute to recovery from sepsis?
• Resolution of inflammation in states other than sepsis
involves specific intracellular pathways and/or events
in immune cells. Which of these events/intracellular
pathways also contribute to resolution of sepsis? What
pathways/events not involved in other states are important for resolution of inflammation in sepsis?
• What events in immune cells that contribute to resolution of nonseptic inflammation promote sepsisinduced immunosuppression, thereby delaying the
resolution of sepsis?
B) What processes related to metabolism and/or bioenergetics
contribute to recovery from cellular and subcellular dysfunction?
What Is Known.
The catabolic state produced by sepsis causes alterations in protein breakdown and is characterized by a reduction in body
weight, lean body mass, skeletal muscle mass, and fat mass. Metabolism, in general, is impaired, but compensatory mechanisms
such as endocrine activity and enhanced substrate availability
mask these abnormalities. For example, while global hepatic glucose production is higher than that observed under nonseptic
conditions, this increase reflects high levels of catecholamines,
corticosteroids, and glucagon. The response of the liver in the
absence of sepsis to equivalent levels of hormonal stimulation
far exceeds that observed during sepsis (184). Hepatic inefficiency at least in part reflects impairment of intracellular signal
transduction pathways for hormones and other mediators (12,
21, 24, 185, 186). Although it is likely that the recovery mechanisms that restore the balance between catabolism and anabolism differ from those that initiated the imbalance, the actual
process is poorly described. Importantly, lean body mass may
be depleted in sepsis but cell death is not a significant feature in
most organs and functional recovery does not appear to be limited by the regenerative capacity of the tissue, perhaps because
solid organ mass does not appear to be affected (187). It is essential to note that metabolic changes during sepsis recovery may
be linked to other subcellular mechanisms, including autophagy,
apoptosis, and proteasome activity (182, 188–190).
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Some aspects of metabolic recovery have been examined
in experimental models, most often using the CLP model in
rodents. Crowell et al (190) studied the regulation of skeletal
muscle protein balance during recovery from CLP in mice.
These investigators noted 1) persistence of CLP-induced proteolysis persisted during the recovery phase, 2) a period of
enhanced muscle protein synthesis that was mediated by activation of Akt-TSC2-mTORC1 signal transduction, and 3)
apparent delay of complete restoration of muscle mass that
was in part explained by continued stimulation of the ubiquitin-proteasome pathway-mediated proteolysis.
Although the erosion of lean body mass and skeletal muscle
loss have been studied (190, 191), examination of sepsisinduced changes in fat mass and adipocyte biology has been
less thorough. The same group also showed that white adipose tissue stimulated continued inflammation with activation of the inflammasome, the ubiquitin-proteasome pathway,
and autophagy, even when the infectious source was excised.
These changes overlapped with alterations in skeletal muscle.
However, release of uncoupling protein 1 during recovery,
suggesting a “browning” of this white adipose tissue, was associated with diminution of inflammasome activation and
autophagy as well as limited lipolysis and lipogenesis (192).
Again, these findings suggest that sepsis-induced changes in
substrate metabolism persist into the recovery phase but that
distinct recovery mechanisms exist.
Some of the mechanisms that modulate the balance between protein breakdown and synthesis also contribute to
control of autophagy, a process that facilitates the turnover of
organelles and intracellular protein. Both skeletal muscle turnover and autophagy are tightly controlled by mTORC1 and
adenosine monophosphate-activated protein kinase (AMPK)
(193). Recovery of AMPK activity following CLP was associated with reduced severity and less profound lung injury (194)
as well as improved bacterial clearance (195).
As described under question 2, bioenergetics are also significantly altered by sepsis. Mitochondrial dysfunction has
been demonstrated in human sepsis and in animal models, including CLP (33, 196–200). Fink termed this block in oxidative
phosphorylation “cytopathic hypoxia” (201). In 2008, Carré
and Singer (202) suggested a link between recovery from sepsis
and mitochondrial biogenesis. This contention is supported
by animal studies demonstrating that recovery was associated
with a progressive increase in cytochrome and mitochondrial
DNA, followed by recovery of oxygen consumption and resting
energy expenditure (203). Additional investigations using CLP
demonstrated improved organ function with reversal or bypass of dysfunction in specific elements of the ETC (204–209).
Recovery in patients was associated with early production of
new mitochondria (biogenesis) (210). Glycolysis contributes
substantially to ATP generation in the presence of sepsisinduced mitochondrial dysfunction (39, 45, 48, 56, 57, 198,
211–213). However, the glycolytic process is complex. Studies
in animals have suggested that it is highly dependent on substrate delivery, Na-K transport (214), stimulation by catecholamines (215), and the Warburg effect (49, 216–218).
www.ccmjournal.org
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What Is Not Known—Gaps in Our Understanding—Directions for Future Research.
1) Does reversal of sepsis-induced changes in metabolism/
energetics promote recovery? Or is reversal of sepsisinduced changes simply an indicator that recovery is
occurring/has occurred?
2) What pathways both mediate sepsis-induced changes in
metabolism and also effect recovery from sepsis? What
pathways that modulate sepsis-induced changes in metabolism do NOT mediate recovery, and vice versa? Can
any of these pathways be manipulated to initiate or enhance recovery from sepsis?
3) Do unexplored or undiscovered pathways mediate both
the development of sepsis-induced changes in metabolism and the recovery from these changes?
4) Can the pathways that mediate recovery from sepsisinduced changes in both protein and fat metabolism be
manipulated to initiate or enhance recovery from sepsis?
5) Can the “browning” of fat be enhanced? Can manipulation
of “browning” be used to enhance recovery from sepsis?
6) Is the restoration of mitochondrial function necessary
for recovery from sepsis?
7) Do interventions that improve the function of individual
aspects of mitochondrial function promote recovery
from sepsis? Do interventions that have been found to
be successful following CLP also enhance recovery from
human sepsis?
8) Recovery requires ATP utilization above basal levels. In
addition to serving as a source of energy production
during sepsis, does ATP production from lactate, that
is, glycolysis, meaningfully contribute to recovery from
sepsis? What mechanisms regulate sepsis-induced lactate
production? Can these mechanisms be manipulated for
therapeutic benefit?
C) What endocrine and neuronal pathways contribute to
recovery from sepsis?
What Is Known.
Endocrine dysfunction is a key characteristic of sepsis; sepsisinduced abnormalities have been reported in the intracellular
pathways mediating tissue responses to nearly every hormone
(19, 20). Dysfunction takes two forms. In the acute phase, tissues become hypo-responsive (“peripheral resistance”) and
central mechanisms to increase hormone release are activated
(19). Ultimately, however, central secretion of hormones, for
example, from the pituitary, decreases (“central suppression”).
Restoration of both tissue responses and central elaboration/
release have been described in recovery (19). However, resolution of sepsis-induced defects in endocrine activity may simply
be a result of recovery as opposed to a contributing factor.
Neuronal abnormalities are believed to contribute to
sepsis pathobiology. For example, recent studies have demonstrated a role for dysfunction in the orexinergic pathway of
the hypothalamus (27) and in the basal forebrain cholinergic
system (28, 219). Seminal work by Pavlov and Tracey (220)
defined the “cholinergic anti-inflammatory pathway,” which
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downregulates inflammation in sepsis via activation of vagus
nerve efferents, leading to sequential splenic release of norepinephrine and then acetylcholine which in turn downregulates
activation of endothelial cells and promotes a pro-resolving
phenotype in macrophages and monocytes. Importantly, the
vagus-mediated anti-inflammatory pathway is impaired following CLP (220). Stimulation of the vagus can reverse some
elements of the CLP-induced inhibition of this reflex (221).
Cognitive defects that may be analogous to those present
in patients with sepsis have been identified following CLP in
rodents. These abnormalities have been attributed to a number
of underlying causes, including neuroinflammation, a number
of different brain regions, most notably the hippocampus
and basal forebrain, and in some cases have been amenable to
treatment (28, 168, 222–231). However, the relevance of these
abnormalities to human sepsis is unknown.
What Is Not Known—Gaps in Our Understanding—Directions
for Future Research.
1) Is reversal of sepsis-induced endocrine/neuronal defects
a cause or an effect of recovery?
2) What specific hormones and/or neuronal pathways contribute to recovery? Are there pathways that are not operative in the pathogenesis of sepsis that are involved in
recovery?
3) Do strategies that counteract or reverse endocrine or
neuronal dysfunction contribute to recovery?
4) What additional neuronal pathways contribute to the
pathogenesis of sepsis?
5) What neuronal abnormalities, pathways, and defects contribute to sepsis-induced short-term neurobehavioral
abnormalities and long-term cognitive dysfunction?

SUMMARY
This document expands upon topics in “Basic Science Research” that were specifically identified as priorities by the SSC
Research Committee (2, 3). The goal of the authors and the
committee was to provide the critical care community with a
detailed, well-balanced, and highly informative summary regarding topics specifically identified by the members of the
SSC Research Committee as a whole. Our focus, and the focus
of future publications, is on “what is known,” followed by enumeration of ongoing research priorities and questions that we
believed are unanswered. Each of the basic research areas that
we have focused on has high translational potential. We have
called upon our collective insights as critical care practitioners
and as investigators focusing on basic science research in sepsis.
We have also included recommendations from other members
of the SSC Research Committee that reflect long-term involvement in the critical care community as a whole.
We recognize that members of the critical care community
have diverse backgrounds and interests and that many are more
clinically focused. We therefore have attempted to provide a balanced and accessible review and perspective and to provide material that is useful to all involved in our specialty. Importantly,
the process used to generate the topics discussed here is, by its
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nature, subjective. Members of the committee all have interests
in/commitments to the study of specific topics. We have tried to
limit the effects of personal interest/bias on the choice of topics.
Similarly, some areas of interest to some readers, of necessity,
will not be represented in this document. Undoubtably some
seeming omissions will be addressed in future papers.
We are grateful to the leadership of the SSC, the ESICM, and
the SCCM for providing the opportunity and for their continued commitment to critical care research.
Dr. Coopersmith’s institution received funding from the National Institutes
of Health. The remaining authors have disclosed that they do not have any
potential conflicts of interest.
For information regarding this article, E-mail: cdeutschman@northwell.edu
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